康希諾AH股齊飆 昨日舉行“新冠疫苗三期生產基地產品下線儀式”
格隆匯4月26日丨康希諾生物-B(06185.HK)和康希諾(688185.SH)均大漲超7%。

昨日,康希諾生物股份公司在天津舉辦了“康希諾生物新冠疫苗三期生產基地產品下線儀式”。 該三期生產基地佔地約15000平方米,設計符合中國和國際通用的GMP標準,設有預灌封注射器灌裝線和西林瓶灌裝線。
基地的生產車間採用康希諾生物具有自主知識產權的腺病毒載體技術平台,該平台具有快速製備病毒載體疫苗的能力,為應對新發、突發重大傳染病疫情防控提供保障。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.